Monisha Das Ireland, MD
Pulmonary Disease · Kansas City, MONPI 1972693919
Payments from drug & device makers
Across 40 payments — averaging $157.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- ZOLL Respicardia, Inc.$3K
- Avadel CNS Pharmaceuticals, LLC$150
- AstraZeneca$135
- Jazz Pharmaceuticals Inc.$100
- Harmony Biosciences LLC$31
- plus $18 from 2 others
What the payments were for
- Travel & lodging$3,23851%
- Food & beverage$3,05649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 23 | $3,296 |
| ZOLL Respicardia, Inc. | 10 | $2,565 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $150 |
| AstraZeneca | 1 | $135 |
| Jazz Pharmaceuticals Inc. | 1 | $100 |
| Harmony Biosciences LLC | 2 | $31 |
| Philips North America LLC | 1 | $11 |
| Itamar Medical Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$2,260
- Inspire Upper Airway Stimulation System$1,660
- Inspire$1,233
- LUMRYZ$150
- FASENRA$135
How this compares
$6,294 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $28,147 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $15,107 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $13,909 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,150 |
| Modafinil | 13 | $1,130 |
| Azelastine Hcl | 38 | $1,060 |
| Pregabalin | 30 | $975 |
| Ventolin HfaAlbuterol Sulfate | 13 | $699 |
| Clonazepam | 38 | $553 |
| Eszopiclone | 26 | $481 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $391 |
| Gabapentin | 31 | $351 |
| Montelukast Sodium | 72 | $345 |
| Fluticasone Propionate | 25 | $308 |
| Armodafinil | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Kansas City
- Mark YaganKansas City$162K
- Timothy SmithKansas City$107K
- Matthew AboudaraKansas City$30K
- Andrea CoveyKansas City$23K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.